Longevity
SLU-PP-332
Metabolic
44
Amino acids
Molecular weight
Peptide
Type
Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.
Top researched benefits
Overview of SLU-PP-332
Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.
metabolic health
- 12% body weight reduction in 28 days without appetite suppression. Fat mass gain <0.5g vs ~5g controls.
- Significantly improved glucose tolerance in obese mice with lower fasting glucose and insulin levels.
- Increases resting energy expenditure by 25% for fatty acid oxidation within 2 hours.
- Reduced hepatic steatosis, decreased hepatic triglycerides, and enhanced hepatic fatty acid oxidation.
exercise performance
- 70% increase in running time and 45% increase in running distance in preclinical models.
- Increased type IIa oxidative skeletal muscle fibers with enhanced oxidative capacity.
cardiovascular
- Improved ejection fraction in heart failure models with reduced cardiac fibrosis.
antiaging
- First compound to reverse age-related mitochondrial dysfunction in 21-month-old mice.
kidney protection
- Reversed age-related albuminuria increase and prevented podocyte loss in elderly mice.
Typical Dose
NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP)
Frequency
Research only - not approved for human use
Cycle Duration
No human protocols established
Storage
2-8°C refrigerated for research use
Chemical Makeup
Key benefits
Exercise mimetic effects without physical activity
12% weight loss in 28 days
70% increased endurance
25% enhanced fatty acid oxidation
Improved insulin sensitivity
Reduced hepatic steatosis
Cardiac protection
Reversal of age-related mitochondrial dysfunction
Community interest
This peptide is still gaining traction in the community.
Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoSLU-PP-332 Molecular Information
View the scientifc details of SLU-PP-332.
44
Amino Acids
SLU-PP-332
Glu
Glu
Position 1
His
His
Position 2
Tyr
Tyr
Position 3
Asp
Asp
Position 4
Arg
Arg
Position 5
Pyl
Pyl
Position 6
?
?
Position 7
Tyr
Tyr
Position 8
Asn
Asn
Position 9
Asn
Asn
Position 10
Ala
Ala
Position 11
Pro
Pro
Position 12
His
His
Position 13
Thr
Thr
Position 14
His
His
Position 15
Ala
Ala
Position 16
Leu
Leu
Position 17
Glu
Glu
Position 18
Asn
Asn
Position 19
Tyr
Tyr
Position 20
Leu
Leu
Position 21
Met
Met
Position 22
Glu
Glu
Position 23
Thr
Thr
Position 24
His
His
Position 25
Tyr
Tyr
Position 26
Leu
Leu
Position 27
Glu
Glu
Position 28
Asn
Asn
Position 29
Glu
Glu
Position 30
Asx
Asx
Position 31
Glu
Glu
Position 32
Asn
Asn
Position 33
Glx
Glx
Position 34
Pyl
Pyl
Position 35
His
His
Position 36
Tyr
Tyr
Position 37
Asp
Asp
Position 38
Arg
Arg
Position 39
Ala
Ala
Position 40
Glx
Glx
Position 41
Ile
Ile
Position 42
Asp
Asp
Position 43
Glu
Glu
Position 44
Molecular Weight
290.32DaChain Length
44Amino AcidsType
PeptideSLU-PP-332 Protocols
Research compound - IP injection in animals only. No human administration protocols established.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Standard Metabolic Protocol | 50 | 2 week range | Intraperitoneal injection (IP) |
| Acute Exercise Enhancement | 50 | 1 week range | Intraperitoneal injection (IP) |
| Extended Treatment | 50 | 4 week range | Intraperitoneal injection (IP) |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- WARNING: Not tested in humans - research only
- Do NOT use outside approved research protocols
- Dosing cannot be extrapolated from animals to humans
- No human clinical trials initiated as of 2025
- Oral formulation in development
- Consult medical professionals before experimental use
SLU-PP-332 Cycle
The SLU-PP-332 Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 0-0
- Metabolic shift toward fat oxidation within 2 hours; gene expression changes at 3-6 hours; enhanced exercise performance 1 hour post-dose
- Week 0-0
- Increased resting energy expenditure measurable; enhanced fatty acid oxidation by 25%; improved grip strength by day 6
- Week 2-4
- Up to 12% weight loss by day 28; dramatic fat mass reduction; improved glucose tolerance; 45-70% endurance improvements; reduced hepatic steatosis
- Week 6-8
- Cardiac improvements (ejection fraction, reduced fibrosis); age-related kidney dysfunction reversal; mitochondrial architecture restoration
- Week 0-0
- Sustained anti-aging effects in aging studies; continued tissue mitochondrial improvement; duration after discontinuation unknown
Dosing tools
SLU-PP-332 Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The dose you want to inject per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
SLU-PP-332
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg SLU-PP-332 vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Reference Guide
Dosing Cycle
- Peptide
- SLU-PP-332
- Dosing
- NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP)
- Dosing Frequency
- Research only - not approved for human use
- Cycle Duration
- No human protocols established
- Storage
- 2-8°C refrigerated for research use
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of SLU-PP-332 interactions with other common peptides and substances.
Weight
5am
Longevity
5-Amino-1MQ
COMPATIBLE
Distinct mechanisms (ERR agonism vs NNMT inhibition) likely complementary without known interactions.
Weight
ipa
Growth
Ipamorelin
COMPATIBLE
May preserve lean muscle during SLU-PP-332-induced fat loss through GH pathway.
Longevity
nad
Metabolic
NAD+
SYNERGISTIC
Complementary mitochondrial pathways - SLU-PP-332 increases biogenesis while NAD+ supports energy production.
Weight
sem
Metabolic
Semaglutide
MONITOR
Combining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely.
Side effects
Monitor: Be careful when combining SLU-PP-332 with Semaglutide.
Contraindications
NOT FOR HUMAN USE - no approved human dose
No human clinical trials conducted
Potential interaction with diabetes medications
Stop signs
Severe hypoglycemia (especially with diabetes medications)
Any cardiovascular symptoms (chest pain, palpitations, shortness of breath)
Signs of liver dysfunction (jaundice, dark urine, severe abdominal pain)
Kidney problems (reduced urination, swelling, severe back pain)
Severe headaches or neurological symptoms
Allergic reactions (rash, hives, difficulty breathing, swelling)
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
SLU-PP-332Research References
SLU-PP-332 is an emerging compound
SLU-PP-332
SLU-PP-332 is an emerging compound
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Diet-induced obese mice, 50 mg/kg IP twice daily, 28 days: 12% body weight loss, 25% fatty acid oxidation increase, improved glucose tolerance, reduced hepatic steatosis.
2024
Synthetic ERRα/β/γ Agonist Induces Acute Aerobic Exercise Response
Multiple mouse models, 50 mg/kg IP: 70% increase in running time, 45% increase in running distance, increased type IIa oxidative muscle fibers.
2023
Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction in Aging Kidney
21-month-old mice, 8-week treatment: Reversed age-related kidney decline, reduced albuminuria, prevented podocyte loss, restored mitochondrial architecture.
2023
Cardiac Protective Effects of Pan-ERR Agonists
Heart failure models, 6-week treatment: Improved ejection fraction, ameliorated cardiac fibrosis, improved survival, enhanced mitochondrial ultrastructure.
2021